Company recently received Emergency Use Authorization for its molecular point-of-care COVID-19 diagnostic test

May 14, 2020 – Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Ingo Chakravarty as President and Chief Executive Officer (CEO) of Mesa Biotech. Chakravarty assumes leadership of the company less than two months after it received Emergency Use Authorization (EUA) from the Federal Drug Administration (FDA) to market its 30-minute point-of-care (POC) molecular SARS-CoV-2 test.

Chakravarty joins Mesa Biotech with more than 25 years of experience and a proven track record in capital formation and building and leading high-performing organizations in the healthcare industry. He most recently served as President and CEO of NAVICAN Genomics after spending nearly two decades building global businesses in the oncology and infectious disease market. He has held senior leadership positions at GenMark Diagnostics, Gen-Probe, Roche, and Ventana Medical Systems.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care. Similar to Mesa Biotech’s commercially available tests for influenza and RSV, the new rapid Accula™ SARS-CoV-2 test provides actionable, laboratory-quality results at POC with greater sensitivity and specificity than traditional infectious disease rapid immunoassay tests.

“Ingo Chakravarty is an accomplished and passionate leader in the healthcare and medical diagnostics fields, and he will be a tremendously valuable addition to Mesa Biotech’s executive team as the company expands its product line to respond to the COVID-19 pandemic,” said Slone Partners CEO Leslie Loveless.

Dr. William Brody, Chairman of the Board of Mesa Biotech, said, “Mesa Biotech has enhanced its market position with the launch of two FDA cleared products for Flu A/ Flu B and RSV, and the more recent Emergency Use Authorization (EUA) for the 30-minute point-of-care Accula SARS-CoV-2 test. Entering our next phase of growth, Mr. Chakravarty is the right person, at the right time, to lead Mesa Biotech.”

“It is remarkable what Mesa Biotech has achieved over the past decade,” said Chakravarty. “I am grateful for the opportunity to be part of such a dedicated, high performing team. Together we will seize the opportunity and be part of the global response to the current and any future infectious disease challenges that require us to quickly generate the most accurate diagnostic data possible – anytime, anywhere.”

Slone Partners delivers the leaders who build amazing scientific healthcare organizations – People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit or call 888.784.3422.

Mesa Biotech designs, develops, manufactures and commercializes next generation rapid molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care. Mesa Biotech’s Accula™ Flu A/Flu B and RSV tests have obtained CE Mark in the EU and 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA). Both products are distributed in the United States by Sekisui Diagnostics under the Silaris™ brand. Mesa Biotech has also secured a number of strategic agreements for distribution in Europe and Asia. For more information visit